Thermo Fisher Beats Estimates With $12B Q2 Revenue, $6.03 Adjusted EPS — Stock Jumps 10%

Thermo Fisher said in a SEC 8-K filing on July 23 (local time) that its Q2 2026 revenue reached $11.99 billion, beating market expectations.

📊 Quote at Time of Writing (Jul 24, 2026, 01:04 KST)
$578.06 ▲ +9.80%

Quarter at a Glance

Thermo Fisher's Q2 revenue rose 10% year-over-year, from $10.85 billion to $11.99 billion. Organic revenue growth — stripping out the effects of new acquisitions and currency — came in at 5%. Adjusted operating margin (adjusted operating income excluding interest, taxes, depreciation and amortization, divided by revenue) improved from 21.9% to 22.8%, showing profitability gains alongside the top-line growth.

• Revenue: $11.99 billion, up 10% year-over-year
• GAAP EPS: $4.68, up 9% year-over-year
• Adjusted EPS: $6.03, up 13% year-over-year
• GAAP operating income: $2.09 billion, up 14% year-over-year
• Adjusted operating income (excluding interest, taxes, depreciation and amortization): $2.73 billion, up 15% year-over-year

Market Reaction

Thermo Fisher shares traded at $578.06 as of early morning July 24, 2026 (Korea time), up 9.80% from the previous close. Foreign media outlets described the results as a strong beat. Investor's Business Daily read the report as a positive signal for the broader medtech sector. Investing.com noted the company raised its full-year outlook alongside the earnings release. During the quarter, the company also repurchased $1.0 billion worth of its own shares.

This article was automatically generated based on the original SEC 8-K filing and international media reports, with the goal of delivering key data quickly after the announcement. Investors are advised to review the company's official filing before making trading decisions. Quotes reflect the time this article was written and may differ from current prices.